An observational study in Intrahepatic Cholestasis, sponsored by Karolinska Institutet. Completed. Open to female participants. Per ClinicalTrials.gov, last updated 2011-06-27.
Sponsored by Karolinska Institutet · Observational
Induction of Labour in Intrahepatic Cholestasis of Pregnancy (ICP) has become a common procedure in management of ICP to avoid fetal complications. Surprisingly, this empirical approach has not been evaluated as to delivery complications and fetal outcome as yet. The investigators now examine weather ICP affects (i) delivery procedures chosen, in particular the incidence of caesarian section, (ii)fetal and maternal outcome in induced labor, and (iii)possible impact of bile acids and UDCA treatment in a retrospective cohort study based on approximately 5000 induced deliveries at Danderyd Hospital, Karolinska Institutet, Stockholm. The investigators analyze data on on previous deliveries, BMI, medical history and medical book data. Primary endpoint is the risk of caesarian section.
220 studies on the registry are indexed under Cholestasis; 37 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 100 across 65 observational studies indexed under Cholestasis.
Browse Cholestasis studies →Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Swedish women affected by ICP delivering at Danderyd Hospital between year 2000-2006.
Exclusion Criteria:
Induction of laborin women with ICP
No ICP
Cesarean section
Time frame: 32 to 40 weeks
Bleeding
Time frame: 32 to 40 weeks
Abruptio placentae
Time frame: 32 to 40 weeks
APGAR
Time frame: 32 to 40 weeks
No study locations are listed for this record.
This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Karolinska Institutet